CD4 and neoplasm: -Induction of TNF-α and IL-12p70 levels (in vitro).-Increased body weights of mice (decreased when NPs administered with adriamycin).-Increased serum TNF-α levels and CD4+/CD8+ lymphocyte ratios and decreased serum IL-10 levels (in vivo).-Increased tumor inhibition rate and decreased tumor growth.